- Home
- TLSA vs MHF Comparison
TLSA vs MHF Comparison
Compare TLSA & MHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLSA | MHF |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.1M | 136.5M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | TLSA | MHF |
|---|---|---|
| Price | $1.18 | $6.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.02 | N/A |
| AVG Volume (30 Days) | ★ 582.2K | 111.0K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.29% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.76 | $5.84 |
| 52 Week High | $2.20 | $7.33 |
Technical Indicators
Market Signals| Indicator | TLSA | MHF |
|---|---|---|
| Relative Strength Index (RSI) | 60.42 | 46.37 |
| Support Level | $1.14 | $5.84 |
| Resistance Level | $1.20 | $6.30 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 76.81 | 68.28 |
Price Performance
Historical ComparisonAbout TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.
About MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.